Company attributes
Pitchbook URL
Legal Name
Cingulate Inc.
Number of Employees (Ranges)
11 – 50
Email Address
clinicaltrials@cingulate.com0
rschultz@cingulate.com0
ir@cingulate.com0
info@cingulate.com0
Phone Number
+19139422300
Full Address
1901 W 47th Place Kansas City, KS 66205, USA0
6 South Street, Suite 203 Morristown, New Jersey 079600
Founded Date
2012
Stock Symbol
CING0
Exchange
Country
Other attributes
Company Operating Status
Active
Ticker Symbol
CING
Cingulate Inc., a clinical-stage biopharmaceutical company, focuses on the development of product candidates for the treatment of central nervous system and neurobiological disorders. The company's lead product candidates are CTx-1301 (dexmethylphenidate) and CTx-1302 (dextroamphetamine) for the treatment of attention deficit/hyperactivity disorders. It also focuses on developing CTx-2103 for the treatment of anxiety disorders. The company was founded in 2012 and is headquartered in Kansas City, Kansas with an additional location in Morristown, New Jersey.
Timeline
No Timeline data yet.
Funding Rounds
Products
Acquisitions
SBIR/STTR Awards
Patents
Further Resources
No Further Resources data yet.
